Acción PMCB PHARMACYTE BIOTECH, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas PharmaCyte Biotech, Inc.

Acciones

PMCB

US71715X2036

Diferido Nasdaq
Otros sitios de cotización
 15:48:22 28/06/2024 		Varia. Cinco días. Varia. 1 de enero.
2,06 USD -0,96 % Gráfico intradía de PharmaCyte Biotech, Inc. +5,64 % -4,63 %
18/03 PharmaCyte Biotech, Inc. presenta los resultados del tercer trimestre y los nueve meses finalizados el 31 de enero de 2024 CI
2023 PharmaCyte Biotech, Inc. presenta los resultados del segundo trimestre y de los seis meses finalizados el 31 de octubre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc.
MyMD Pharmaceuticals, Inc. amended terms of the transaction
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
MyMD Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc.
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors
Femasys Inc. announces tranche update
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc.
PharmaCyte Biotech : Change in Certifying Accountants - Form 8-K
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023
PharmaCyte Biotech : Certificate of Incorporation/Bylaws - Form 8-K
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción PMCB
  4. Noticias PharmaCyte Biotech, Inc.
  5. Otros idiomas